Xtl Biopharmaceuticals (XTLB) Return on Assets (2009 - 2025)

Xtl Biopharmaceuticals (XTLB) has reported Return on Assets for 17 consecutive years, with 0.03% the latest figure, recorded in Q4 2025.

• Quarterly Return on Assets rose 3.0% year-over-year to 0.03% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.03% (up 3.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
• Return on Assets improved to 0.03% in Q4 2025 per XTLB's latest filing, from 0.0% in the prior quarter.
• Over the last five years, Return on Assets for XTLB reached as high as 0.03% in Q4 2025 and fell as low as 0.01% in Q3 2023.
• A 5-year average of 0.0% and a median of 0.0% in 2022 frame the typical range for Return on Assets.
• Annual changes were most pronounced in 2023 — Return on Assets dropped 1 bps — and 2025, when it rose 3 bps.
• Year by year, Return on Assets stood at 0.0% in 2021, then jumped by 70 bps to 0.0% in 2022, then plunged by 1291 bps to 0.01% in 2023, then jumped by 77 bps to 0.0% in 2024, then soared by 2251 bps to 0.03% in 2025.
• According to Business Quant data, Return on Assets over the past three periods registered 0.03%, 0.0%, and 0.0% for Q4 2025, Q2 2025, and Q4 2024 respectively.